Drugs & Targets Amgen and Allergan submit BLA for biosimilar candidate to Rituxan January 03, 2020Vol.46 No.01
Drugs & Targets China approves Zejula as maintenance therapy for recurrent ovarian cancer January 03, 2020Vol.46 No.01
Drugs & TargetsFree FDA issues draft guidance to foster pediatric oncology product development December 13, 2019Vol.45 No.46
Drugs & TargetsFree FDA approves Avsola for same indications as Remicade December 13, 2019Vol.45 No.46
Drugs & TargetsFree FDA grants Janssen’s BCMA CAR-T therapy JNJ-4528 Breakthrough Therapy Designation for multiple myeloma indication December 13, 2019Vol.45 No.46
Drugs & Targets FDA approves Tecentriq + chemo as initial treatment metastatic non-squamous NSCLC indication December 06, 2019Vol.45 No.45
Drugs & Targets FDA approves FoundationOne CDx as a Companion Diagnostic for Piqray in new indication December 06, 2019Vol.45 No.45
Drugs & Targets FDA grants Priority Review to Merck’s Supplemental Biologics License Application for Keytruda in NMIBC indication December 06, 2019Vol.45 No.45
Drugs & Targets FDA accepts NDA for pemigatinib in previously treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements December 06, 2019Vol.45 No.45
Drugs & Targets China approves Keytruda for first-line treatment in metastatic squamous NSCLC+chemo indication December 06, 2019Vol.45 No.45
